logo

Slide Shows

Share
Events

Biotech Stocks Facing FDA Decision In December 2022 Now, let’s take a look at the biotech stocks facing FDA decision in December.

Biotech Stocks Facing FDA Decision In November 2022 The FDA has approved 28 novel drugs so far this year, including 2 in October

Biotech Stocks Facing FDA Decision In October 2022 The FDA has approved only 24 novel drugs this year (Jan. to Sep.) compared to 40 during the same period last year.

Biotech Stocks Facing FDA Decision In September The month of August witnessed the FDA approving the first cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who require regular blood transfusions on Aug.17. This one-time gene therapy by the name Zynteglo, developed by bluebird bio Inc. (BLUE), reportedly carries a price tag of $2.8 million.